sar425899 dual agonist glp-1 glucagon sanofi Transforming obesity: The advancement of multi-receptor drugs: Cell Gut hormone-based pharmacology: novel formulations

One of the most appealing features for our patients is Ozempics convenient once-weekly dosing schedule

Figure 35: Diagram showing action of GLP-1, GIP (incretins) and DPP-4 inhibitors, credit: Ilmari Karonen, Wikimedia

J Lipid Res (1994) 35(9):153541

The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients